PACCT: Partnering Around Cancer Clinical Trials
2 other identifiers
interventional
316
1 country
2
Brief Summary
This research has the overall goal of increasing rates at which African American and White men with prostate cancer make an informed decision to participate in a cancer clinical trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable prostate-cancer
Started Sep 2016
Typical duration for not_applicable prostate-cancer
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 8, 2016
CompletedFirst Posted
Study publicly available on registry
September 20, 2016
CompletedStudy Start
First participant enrolled
September 20, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 17, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 17, 2021
CompletedResults Posted
Study results publicly available
January 17, 2023
CompletedJanuary 17, 2023
December 1, 2022
4.8 years
September 8, 2016
August 22, 2022
December 20, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Physician Offers of a Clinical Trial
Single item: Did the physician offer a trial?
Day of clinical interaction; up to 2 years following enrollment
Secondary Outcomes (7)
Patient Decisions to Enroll in a Trial
1 week following clinical interaction
Patient Active Participation
Day of clinical interaction; up to 2 years following enrollment
Quality of Informed Consent (Modified)
1 week following clinical interaction
Patient Enrollment in Trial
3 months following clinical interaction
Physician Patient-Centered Communication
Day of clinical interaction; up to 2 years following enrollment
- +2 more secondary outcomes
Study Arms (3)
Patients--Intervention
EXPERIMENTALPatients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
Patients--Usual Care
NO INTERVENTIONPatients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
Physicians
OTHERPhysicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
Interventions
This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
Eligibility Criteria
You may qualify if:
- Treat patients with prostate cancer
- Able to recruit patients to clinical trials
You may not qualify if:
- Do not treat patients with prostate cancer
- Not able to recruit patients to clinical trials
- Patient Participants
- Black, African American or White; Non-hispanic confirmed diagnosis of prostate Cancer
- Seeing a participating physician for less than a year and expect to see this physician at least once in the coming year
- Able to read and write English well enough to understand and sign consent forms and respond to questionnaires
- Not black, African American or White; non Hispanic
- No confirmed diagnosis of prostate cancer
- Not seeing a participating physician or seeing a participating physician for \> than one year
- Not able to read and write English well enough to understand and sign consent forms and respond to questionnaires
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Susan Egglylead
- National Cancer Institute (NCI)collaborator
Study Sites (2)
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer
Baltimore, Maryland, 21287, United States
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Related Publications (2)
Eggly S, Manning M, Senft N, Moore TF, Albrecht TL, Penner LA, Heath E, Carducci MA, Lansey DG, Hamel LM. Development and pilot test of a physician-focused cancer clinical trials communication training intervention. PEC Innov. 2021 Dec 16;1:100012. doi: 10.1016/j.pecinn.2021.100012. eCollection 2022 Dec.
PMID: 37364021DERIVEDEggly S, Hamel LM, Heath E, Manning MA, Albrecht TL, Barton E, Wojda M, Foster T, Carducci M, Lansey D, Wang T, Abdallah R, Abrahamian N, Kim S, Senft N, Penner LA. Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials. BMC Cancer. 2017 Dec 2;17(1):807. doi: 10.1186/s12885-017-3804-5.
PMID: 29197371DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Susan Eggly, PhD
- Organization
- Wayne State University/Karmanos Cancer Institute
Study Officials
- PRINCIPAL INVESTIGATOR
Susan Eggly, Ph.D.
Wayne State University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 8, 2016
First Posted
September 20, 2016
Study Start
September 20, 2016
Primary Completion
July 17, 2021
Study Completion
July 17, 2021
Last Updated
January 17, 2023
Results First Posted
January 17, 2023
Record last verified: 2022-12